[
  {
    "ts": "2025-12-25T02:05:00+00:00",
    "headline": "Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies",
    "summary": "Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management fie",
    "url": "https://finance.yahoo.com/news/caliways-fat-reduction-drug-candidate-020500815.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "275dceb5-bed9-33b6-b0c8-8ed3f7c655a6",
      "content": {
        "id": "275dceb5-bed9-33b6-b0c8-8ed3f7c655a6",
        "contentType": "STORY",
        "title": "Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies",
        "description": "",
        "summary": "Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management fie",
        "pubDate": "2025-12-25T02:05:00Z",
        "displayTime": "2025-12-25T02:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd39",
          "originalWidth": 400,
          "originalHeight": 118,
          "caption": "Caliway Biopharmaceuticals (PRNewsfoto/Caliway Biopharmaceuticals)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a5AnGJR.rdINSCnWGbgkAg--~B/aD0xMTg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd39.cf.webp",
              "width": 400,
              "height": 118,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.f0eEj_4woeYc9Ub4_xv5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd39.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/caliways-fat-reduction-drug-candidate-020500815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/caliways-fat-reduction-drug-candidate-020500815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]